流式细胞术检测骨髓增生异常综合征免疫表型分析及临床应用前景  

Immunophenotyping of myelodysplastic syndromes by flow cytometry and its potential clinical application

作　　者：王斐[1] 徐淑琴[1] 崔巍[1] 

机构地区：[1]中国医学科学院北京协和医学院北京协和医院检验科,100730

出　　处：《中华检验医学杂志》2016年第5期332-335,共4页Chinese Journal of Laboratory Medicine

摘　　要：骨髓增生异常综合征（MDS）是一组复杂的造血干细胞克隆性疾病，当无典型形态、细胞遗传学证据时，传统MDS的诊断方法将遇到极大的挑战。流式细胞术（FCM）在检测髓系异常造血的高灵敏性使其在鉴别诊断各种原因引起的血细胞减少方面具有独特的应用价值。但由于MDS分型具有异质性，尚未发现MDS特异性的抗原标志或标志组合，这使得流式细胞术MDS免疫分型尚存在一定的难度。本文将结合国内外共识着重对如何采用流式细胞术进行MDS免疫表型分析以及流式细胞术在MDS诊断、预后判断、治疗监测等方面的临床应用前景进行阐述。Myelodysplastic syndromes （MDS） is a heterogeneous group of clone bone marrow disorders. The diagnosis of MDS can be challenging when dysplastic features are minimal and cytogenetic analysis shows no abnormalities. The high sensitivity of flow cytometry （FCM） in the detection of dysplasia in myeloid lineages makes it a valuable tool to distinguish possible clonal causes of cytopenia（s） from non- clonal causes. Due to the heterogeneity and absence of specific FCM markers for MDS, the immunophenotyping of MDS by FCM remains a big difficulty. Here we will focus on how to perform immunophenotyping of MDS by FCM and the potential diagnostic, prognostic and therapeutic value of FCM in MDS.

关 键 词：骨髓增生异常综合征 免疫表型分型 流式细胞术 

分 类 号：R551.3[医药卫生—血液循环系统疾病]